KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Operating Margin (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Operating Margin data on record, last reported at 1.19% in Q4 2025.

  • For Q4 2025, Operating Margin fell 1200.0% year-over-year to 1.19%; the TTM value through Dec 2025 reached 2.64%, up 1311.0%, while the annual FY2025 figure was 2.64%, 1311.0% up from the prior year.
  • Operating Margin reached 1.19% in Q4 2025 per PCRX's latest filing, down from 3.54% in the prior quarter.
  • Across five years, Operating Margin topped out at 25.7% in Q2 2021 and bottomed at 82.77% in Q3 2024.
  • Average Operating Margin over 5 years is 6.06%, with a median of 10.91% recorded in 2022.
  • Peak YoY movement for Operating Margin: plummeted -9358bps in 2024, then surged 8631bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 2.65% in 2021, then tumbled by -321bps to 5.84% in 2022, then soared by 413bps to 18.3% in 2023, then fell by -28bps to 13.19% in 2024, then tumbled by -91bps to 1.19% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 1.19% in Q4 2025, 3.54% in Q3 2025, and 4.69% in Q2 2025.